Epithalon for Sale USA: No Customs, Still One Page of COA

Epithalon for sale USA narrows a global market to a domestic one, and the narrowing is worth something specific and worth less than it is usually sold as. It removes a border, shortens a journey and keeps a return path open. It adds nothing whatsoever to the document that describes the powder.

That document is the only part of the transaction carrying information about the material, and it is produced once, at the point of manufacture, before the question of which warehouse the lot ends up in has been decided. A domestic seller and an overseas seller shipping vials from the same batch are offering identical evidence. What differs is everything around the vial.

The domestic listing this page examines:

What Epithalon for sale USA actually changes

Four things change and one does not, and separating them is most of the value this page can add.

The last row is the one worth sitting with. Six results on a single page is a stronger document than most of this market produces, and every one of them would read the same if the vial had shipped from anywhere else. We made the same argument about a different compound, where the temptation to treat domestic stock as a quality signal is just as strong, in our reading of what domestic Selank supply is worth.

One page, six results, and a date on all of them

The certificate for batch 15-05260628 was certified on 23 May 2026 by Kovera Labs under report KVR-2026-A36FF4. It reports purity at 99.312 percent against a specification of greater than 98 percent, identity confirmed by liquid chromatography with mass spectrometry, an endotoxin safety screen passed against a limit of 0.5 EU/mL or below, a microbial sterility screen returning no growth, arsenic, cadmium, lead and mercury each negative, and net content measured at 9.64 mg against a 10 mg label with a stated tolerance of 10 percent.

The net content line is the one that tells you something about the seller rather than the powder. It is inside tolerance, it is under the label, and publishing it moves the real figure on that batch from $2.50 to $2.59 per milligram at the discounted price. Vendors do not usually print numbers that cost them money. The full working is in our breakdown of what an Epithalon milligram costs.

Two candid observations about the same document. It runs to one page, and three of its six results are outcomes rather than measurements: the endotoxin screen is a pass rather than a concentration, the sterility screen is a no-growth rather than a compendial test, and the metals are negatives rather than values under stated limits. The certificate also does not name the method behind the endotoxin result, where the compendial reference procedure would be USP Chapter 85. The same supplier has issued longer documents with numeric endotoxin figures and named assays on other compounds, which we set out in our analysis of what a Semax milligram costs. That difference is a property of the document, and it travels with the batch regardless of which country the batch is stored in.

It is also worth being precise about what domestic transit protects, because cold chain is the phrase sellers reach for and it is doing less work here than it would for a solution. A lyophilised solid is stable largely because the water that drives hydrolysis has been removed, which is why a freeze-dried peptide tolerates a few days in a warm truck far better than a reconstituted one would tolerate a few hours. What a short domestic journey buys is fewer handovers, fewer temperature excursions and less cumulative time at ambient, all of which are real and none of which are dramatic. The failure mode a long import actually introduces is not usually thermal. It is a parcel sitting undelivered while a decision is made about it.

Every result also carries a date, and the date is the part domestic supply cannot help with. A certificate is a photograph of a batch at a moment. Warehousing a lot in Texas rather than in Guangdong does not re-run the assay, and a vial sold eighteen months after certification is covered by a document eighteen months old wherever it was stored. Ask which lot is currently shipping, not which lot the website has a PDF for.

Why no US pharmacy has this on a shelf

A reader who finds domestic research-supply listings reasonably asks why the ordinary medical channel is absent. The answer is on two FDA documents and it is unusually clean.

There is no FDA-approved drug product containing epitalon, so there is nothing for a prescriber to prescribe and nothing for a pharmacy to dispense. That leaves compounding, and compounding from a bulk substance under section 503A requires the substance to satisfy one of a small set of statutory conditions, of which the relevant one here is appearing on the 503A bulks list. Epitalon does not appear on it. The list updated on 14 May 2026 sorts nominated substances into three categories, and epitalon is in none of them.

The reason it is in none of them is the interesting part. It was nominated. FDA placed it in category 2 under the interim policies, the bucket for substances that raise significant safety concerns. It then appears in the agency’s table of substances that were previously in category 2 and were withdrawn by the nominators. So the sequence is nominated, flagged, withdrawn, and the withdrawal was the nominator’s act rather than a refusal by the agency. The practical result is the same either way: no bulks-list entry, no compounding route, no pharmacy shelf. The precise version of that story, including what FDA did and did not say, is in our account of the regulatory position on Epithalon.

What the border does to an overseas order

Buying domestically is partly a way of not finding out. An imported parcel containing an unapproved drug substance is exposed to a detention decision made at the port, and FDA maintains an import alert specifically covering detention without physical examination of unapproved new drugs promoted in the United States. Unapproved is exactly this compound’s status. The agency’s personal importation guidance describes narrow circumstances in which enforcement discretion may be exercised, and those circumstances were written with patients carrying treatments for serious conditions in mind, not with research chemicals ordered from a website.

None of that is a prediction about any individual shipment, because port decisions are discretionary and most parcels are never examined. It is a description of the risk being carried. A detained parcel is money spent with nothing arriving and no return path, and the buyer who paid an overseas seller in cryptocurrency has no second route to recovery either. Domestic stock retires that entire category of problem, and that, rather than any quality claim, is what it is worth paying a premium for if a premium is being charged.

Verifying a domestic claim before you pay

A phrase like ships from the USA is a marketing string until something confirms it. Four questions turn it into a checkable claim, and all four can be asked before an order is placed.

• Which state does it dispatch from, and what carrier? A seller holding stock can answer immediately. A seller drop-shipping from overseas will answer in generalities, and the tracking number that arrives later will resolve the question anyway.
• What batch is currently shipping? This is the strongest of the four. A seller who names the lot before you order is describing inventory in a building. One who can only point at a PDF on a product page may not know what is on the shelf.
• Where would a return go? A domestic return address is the difference between a dispute and a write-off, and it is a fact a legitimate operation has to hand.
• How is it paid for?Card payment leaves a chargeback route open. Bank transfer and cryptocurrency do not, and a seller who only accepts the latter has removed the buyer’s recourse regardless of where the parcel physically originates.

Nothing on this page changes what the compound is or is not known to do. Epithalon is a synthetic tetrapeptide, four residues, Ala-Glu-Asp-Gly, PubChem CID 219042, formula C14H22N4O9, molecular weight 390.35, filed by FDA and PubChem under the spelling Epitalon. It is marketed on telomere and longevity claims that trace largely to a single research group, and this site reports those claims rather than adopting them. FDA states that compounded drugs containing epitalon may pose a risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities, and that it lacks sufficient information to know whether the drug would cause harm if administered to humans. A domestic warehouse does not alter a word of that.